Discovery of pyrrolopyrimidine inhibitors of Akt von Blake, James F., Kallan, Nicholas C., Xiao, Dengming, Xu, Rui, Bencsik, Josef R., Skelton, Nicholas J., Spencer, Keith L., Mitchell, Ian S., Woessner, Richard D., Gloor, Susan L., Risom, Tyler, Gross, Stefan D., Martinson, Matthew, Morales, Tony H., Vigers, Guy P.A., Brandhuber, Barbara J.

Volltext

Discovery and SAR of spirochromane Akt inhibitors von Kallan, Nicholas C., Spencer, Keith L., Blake, James F., Xu, Rui, Heizer, Justin, Bencsik, Josef R., Mitchell, Ian S., Gloor, Susan L., Martinson, Matthew, Risom, Tyler, Gross, Stefan D., Morales, Tony H., Wu, Wen-I, Vigers, Guy P.A., Brandhuber, Barbara J., Skelton, Nicholas J.

Volltext

The mechanism of CSF arrest in vertebrate oocytes von Maller, James L, Schwab, Markus S, Gross, Stefan D, Taieb, Frédéric E, Roberts, B.Tibor, Tunquist, Brian J

Volltext

Discovery of spirocyclic sulfonamides as potent Akt inhibitors with exquisite selectivity against PKA von Xu, Rui, Banka, Anna, Blake, James F., Mitchell, Ian S., Wallace, Eli M., Bencsik, Josef R., Kallan, Nicholas C., Spencer, Keith L., Gloor, Susan L., Martinson, Matthew, Risom, Tyler, Gross, Stefan D., Morales, Tony H., Wu, Wen-I, Vigers, Guy P.A., Brandhuber, Barbara J., Skelton, Nicholas J.

Volltext

Elvn-001, a Next Generation ATP-Competitive ABL1 Tyrosine Kinase Inhibitor for the Treatment of Chronic Myeloid Leukemia von Gross, Stefan D, Eide, Christopher A., Burkard, Michael R, Reister Schultz, Anna, Aujay, Monette A, Kintz, Samuel, Druker, Brian J., Lyssikatos, Joseph P

Volltext

Abstract 4019: Preclinical activity of ELVN-002: A potent, selective, and irreversible HER2 and pan-HER2 mutant small molecule inhibitor for the treatment of HER2 driven malignanci... von Aujay, Monette, Broad, Amanda J., Gross, Stefan D., Ren, Li, Lyssikatos, Joseph P., Kintz, Samuel, Wang, Qi, Collins, Helen

Volltext

Cell Cycle-Dependent Localization of Casein Kinase I to Mitotic Spindles von Brockman, Jennifer L., Gross, Stefan D., Sussman, Michael R., Anderson, Richard A.

Volltext

Casein Kinase I α and αL:  Alternative Splicing-Generated Kinases Exhibit Different Catalytic Properties von Zhang, Jiren, Gross, Stefan D, Schroeder, Matthew D, Anderson, Richard A

Volltext

Casein Kinase I: Spatial Organization and Positioning of a Multifunctional Protein Kinase Family von Gross, Stefan D., Anderson, Richard A.

Volltext

A Constitutively Active Form of the Protein Kinase p90Rsk1 Is Sufficient to Trigger the G2/M Transition in Xenopus Oocytes von Gross, Stefan D., Lewellyn, Andrea L., Maller, James L.

Volltext

The pathway of MAP kinase mediation of CSF arrest in Xenopus oocytes von Maller, James L., Schwab, Markus S., Roberts, B.Tibor, Gross, Stefan D., Taieb, Frédéric E., Tunquist, Brian J.

Volltext

The critical role of the MAP kinase pathway in meiosis II in Xenopus oocytes is mediated by p90(Rsk) von Gross, S D, Schwab, M S, Taieb, F E, Lewellyn, A L, Qian, Y W, Maller, J L

Volltext

Bub1 is activated by the protein kinase p90 Rsk during Xenopus oocyte maturation von Schwab, Markus S, Roberts, B.Tibor, Gross, Stefan D, Tunquist, Brian J, Taieb, Frédéric E, Lewellyn, Andrea L, Maller, James L

Volltext

Induction of Metaphase Arrest in Cleaving Xenopus Embryos by the Protein Kinase p90$^{Rsk} von Gross, Stefan D., Schwab, Markus S., Lewellyn, Andrea L., Maller, James L.

Volltext

The critical role of the MAP kinase pathway in meiosis II in Xenopus oocytes is mediated by p90Rsk von Gross, Stefan D, Schwab, Markus S, Taieb, Frederic E, Lewellyn, Andrea L, Qian, Yue-Wei, Maller, James L

Volltext

Activation of the anaphase-promoting complex and degradation of cyclin B is not required for progression from Meiosis I to II in Xenopus oocytes von Taieb, Frédéric E., Gross, Stefan D., Lewellyn, Andrea L., Maller, James L.

Volltext

Bub1 is activated by the protein kinase p90(Rsk) during Xenopus oocyte maturation von Schwab, M S, Roberts, B T, Gross, S D, Tunquist, B J, Taieb, F E, Lewellyn, A L, Maller, J L

Volltext

Abstract 551: A potent and selective cFMS inhibitor regulates the tumor macrophage microenvironment leading to tumor growth inhibition von Wright, Albion D., Willis, Brandon S., Gomez, Anna, Boys, Mark L., DeLisle, Robert K., Burgess, Laurence E., Munson, Mark C., Kennedy, April L., Topalov, George T., Zhao, Qian, Rodriguez, Martha E., Rast, Bryson, Rizzi, James P., DeWolf, Walter E., Lemieux, Christine, Anderson, Deborah, Neale, Jason R., Martinson, Matthew, Gross, Stefan D., Callejo, Michele, Risom, Tyler, Lee, Patrice A.

Volltext

Abstract B267: AR-mTOR-1: A potent, selective mTORC 1/2 kinase inhibitor for the treatment of malignancy von Wallace, Eli M., Xu, Rui, Josey, John, Gross, Stefan D., DeMeese, Lisa, Fischer, John, Miknis, Greg, Humphries, Mike, Regal, Kelly, Fell, Brad, Burkard, Michael, DeWolf, Walt E., Gloor, Susan, Hastings, Gregg, Zuzack, John, Winkler, James, Koch, Kevin

Volltext

Abstract 4484: AR-mTOR-26 - A potent, selective mTORC 1/2 kinase inhibitor for the treatment of malignancy von Gross, Stefan D., Xu, Rui, Boys, Mark, Condroski, Kevin, DeMeese, Lisa, DeWolf, Walt E., Fell, Brad, Fischer, John, Gloor, Susan, Humphries, Michael J., Miknis, Greg, Regal, Kelly, Rodriguez, Mareli, Raddatz, Nicholas, Shotts, Kristin, Topalov, Georg, Wallace, Eli, Zuzack, John, Josey, John A., Winkler, James, Koch, Kevin

Volltext